Zambon in the USA
Interview with Thibaud Eckenschwiller, Zambon USA CEO & President
Our BOSTON and PROMIS programs are of utmost importance in the US and globally since BOS and NCFB are severe respiratory diseases. The unmet need is very high and urgent as there are no approved treatments currently indicated for these patients.
Zambon USA Team
Together with their European colleagues, the American team has been laying the groundwork in preparation for two commercial launches, pending positive data and receiving the necessary regulatory approvals.
Mr. Eckenschwiller is a Pharma executive veteran with over 30 years of experience in various leadership roles (finance, sales, general management) throughout Europe and recently in the US.
As Head of Global Business Operations, Mr. Eckenschwiller leads global strategic marketing, business development, and market access at Zambon. He is a member of Zambon’s Executive Committee and Chief Executive Officer of Zambon USA Ltd., heading US operations and the company’s US entry strategy.
Prior, Mr. Eckenschwiller served as President and Managing Director of the Italian branch at Ipsen. During his tenure, the affiliate underwent a cultural transformation that led to a sales growth acceleration, positioning Ipsen among the leading companies in terms of growth in Italy, and successfully launching three new oncology products during the last two years with the company. Before moving to Italy, he also led Ipsen’s Spanish affiliate, increasing profitability and market share during the country's worst economic crisis.
At Ipsen, Mr. Eckenschwiller had the opportunity to actively participate in the company’s transformation, joining in 2003 to prepare for the company’s IPO, and following to develop the emerging markets (Latin America, Middle East and South East Asia), contributing to Ipsen’s international development, as well as to the growth of its Specialty Care business.
During this period (2015-2018), Mr. Eckenschwiller was also the President of Club Santé Italie, a Think Tank whose members consisted of 40 leading French healthcare companies operating in Italy (with cumulative sales of approximately 3bn € with 10,000 employees in Italy).
Earlier in his career, he spent 12 years at Novartis in Switzerland, Denmark and Italy where he had increasing responsibilities in Finance.
Mr. Eckenschwiller graduated in Biochemistry from the ETH Zurich. He is French National and fluently speaks French, Italian, English, Spanish and German. He has been a French Foreign Trade Advisor since 2016, having been nominated by the Prime Minister of France.
Mr. Shadday has more than 20 years of global commercial expertise in strategic and operational marketing and sales functions with leadership roles in US, Europe, Latin America and Asia Pacific.
He is responsible for the development of Zambon’s USA affiliate and leading the commercial organization for Zambon’s US CNS, anti-infective and severe respiratory disease portfolios. In his role as Head of Global Marketing Specialty Care, he is responsible for Zambon’s global CNS and severe respiratory drug portfolios. Prior, he served as the Chief Commercial Officer at Breath Therapeutics, until the company’s acquisition by Zambon SpA in 2019. Earlier, Mr. Shadday was the Global Marketing Lead at Vertex for its next-generation corrector programs for the treatment of cystic fibrosis. Previously, he served as Vice President and Global Business Leader at Lundbeck and led the global product launch of Brintellix/Trintellix, a novel antidepressant and key brand. Prior, Mr. Shadday served as Director of International and Global Commercial Strategy at Gilead Sciences and was responsible for the hepatitis, anti-fungal and respiratory therapeutic franchises. At Gilead, he also oversaw the U.S. and international commercial teams for the global commercial launch of Viread for Hepatitis B. Earlier in his career, Mr. Shadday held several commercial positions with Novartis in Europe, the US and South America.
Mr. Shadday earned a Bachelor of Arts degree in Economics from Yale University and is a graduate of the Ecole Supérieure de Commerce de Paris. He holds a dual US and French Citizenship and is fluent in French, German, English and Spanish.